(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 23.42% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.73%.
Grail's revenue in 2026 is $156,120,000.On average, 10 Wall Street analysts forecast GRAL's revenue for 2026 to be $7,866,611,497, with the lowest GRAL revenue forecast at $7,234,020,916, and the highest GRAL revenue forecast at $8,341,269,015. On average, 10 Wall Street analysts forecast GRAL's revenue for 2027 to be $9,818,458,147, with the lowest GRAL revenue forecast at $8,495,768,750, and the highest GRAL revenue forecast at $11,270,326,488.
In 2028, GRAL is forecast to generate $12,760,390,597 in revenue, with the lowest revenue forecast at $10,714,127,442 and the highest revenue forecast at $15,762,835,443.